Dasatinib

Generic Name
Dasatinib
Brand Names
Sprycel
Drug Type
Small Molecule
Chemical Formula
C22H26ClN7O2S
CAS Number
302962-49-8
Unique Ingredient Identifier
X78UG0A0RN
Background

Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...

Indication

Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...

Associated Conditions
Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-
Clinical Trials
Related News

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

First Posted Date
2021-02-10
Last Posted Date
2024-11-22
Lead Sponsor
University of Chicago
Target Recruit Count
25
Registration Number
NCT04747912
Locations
🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

First Posted Date
2020-10-08
Last Posted Date
2024-06-03
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
59
Registration Number
NCT04580121
Locations
🇮🇹

Ospedale Santa Chiara; Unita Operativa Di Ematologia, Pisa, Toscana, Italy

🇺🇸

UC Davis Comprehensive Cancer Center, Sacramento, California, United States

🇩🇰

Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT, København Ø, Denmark

and more 20 locations

A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)

First Posted Date
2020-10-08
Last Posted Date
2020-10-08
Lead Sponsor
National Research Center for Hematology, Russia
Target Recruit Count
100
Registration Number
NCT04578847
Locations
🇷🇺

National Research Center for Hematology, Moscow, Russian Federation

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

First Posted Date
2020-08-28
Last Posted Date
2024-12-17
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
348
Registration Number
NCT04530565
Locations
🇺🇸

Cancer Hematology Centers - Flint, Flint, Michigan, United States

🇺🇸

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

🇺🇸

Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States

and more 203 locations

Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

First Posted Date
2020-06-19
Last Posted Date
2020-07-20
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT04439305
Locations
🇺🇸

ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

First Posted Date
2020-04-01
Last Posted Date
2024-07-24
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
17
Registration Number
NCT04329325
Locations
🇺🇸

Mount Sinai Hospital, New York, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

Phase 2
Completed
Conditions
Healthy
Interventions
Drug: Fisetin
Drug: Dasatinib
Drug: Quercetin
First Posted Date
2020-03-18
Last Posted Date
2024-07-22
Lead Sponsor
Sundeep Khosla, M.D.
Target Recruit Count
74
Registration Number
NCT04313634
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

First Posted Date
2019-11-15
Last Posted Date
2023-12-12
Lead Sponsor
Anne Noonan
Target Recruit Count
9
Registration Number
NCT04164069
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP

First Posted Date
2019-11-07
Last Posted Date
2022-07-27
Lead Sponsor
Shenzhen Second People's Hospital
Target Recruit Count
65
Registration Number
NCT04155411
Locations
🇨🇳

Xin Du, Shenzhen, Guangdong, China

Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia

First Posted Date
2019-11-01
Last Posted Date
2024-11-26
Lead Sponsor
Masaryk University
Target Recruit Count
150
Registration Number
NCT04147533
Locations
🇨🇿

University Hospital Kralovske Vinohrady, Praha, Czechia

🇨🇿

Insitute of Hematology and Blood Transfusion, Praha, Czechia

🇨🇿

University Hospital Plzen, Plzen, Czechia

and more 5 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy